Clinical Trials Browser

Phase 2 × sepantronium × Breast × Clear all

NCT01038804 2013-09-18

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis